Michael Kinch, Ph.D.

Michael Kinch
Professor

Director, Center for Drug Discovery

Publications (PubMed / NIH)

Phone: 314-362-4525
Email: michael.kinch@wustl.edu

 

Research

We analyze the science, medicine and business of the biopharmaceutical enterprise through the Center for Research Innovation in Biotechnology (CRIB), assessing trends that govern the research and development of new medicines. Based on such findings and my role in helping lead innovation and entrepreneurship activities at Washington University, we created the Center for Drug Discovery (CDD) to identify and underwrite the most promising drug discovery projects at Washington University using a novel combination of internal and external expertise.


Select Patents

Title: Epha2 t-cell epitope agonists and uses therefore
Patent #: US20190023756
Kind: A1
Inventor(s): Walter J. Storkus, Michael S. Kinch
Abstract:
EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient’s immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient’s immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

Google Patents Link

Select Publications

Michael Kinch (2019). “The End of the Beginning: Cancer, Immunity, and the Future of a Cure” ISBN-13: 978-1643130255, ISBN-10: 1643130250

Griesenauer R.H., Schillebeeckx C., & Kinch M.S. (2019). “Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases.” Drug Discov Today. 2019 Jan 25. pii: S1359-6446(18)30258-7. doi: 10.1016/j.drudis.2019.01.010. [Epub ahead of print] (Abstract)

Kinch M.S. & Griesenauer R.H. (2018). “2017 in review: FDA approvals of new molecular entities.” Drug Discov Today. 2018 May 8. pii: S1359-6446(18)30088-6. doi: 10.1016/j.drudis.2018.05.011. (Abstract)

Michael Kinch (2018). “Between Hope and Fear: A History of Vaccines and Human Immunity” ISBN-13: 978-1681777511, ISBN-10: 1681777517

Griesenauer R.H., Moore R., & Kinch M.S. (2017). “NIH Support for FDA-Approved Medicines.” Cell Chem Biol. 2017 Nov 16;24(11):1315-1316. doi: 10.1016/j.chembiol.2017.11.002. (Abstract)

Griesenauer R.H. & Kinch M.S. (2017). “An overview of FDA-approved vaccines & their innovators.” Expert Rev Vaccines. 2017 Dec;16(12):1253-1266. doi: 10.1080/14760584.2017.1383159. Epub 2017 Sep 25. (Abstract)

Griesenauer R.H. and Kinch M.S. (2017). “2016 in review: FDA approvals of new molecular entities.” Drug Discov Today. 2017 Nov;22(11):1593-1597. doi: 10.1016/j.drudis.2017.06.011. Epub 2017 Jul 4. (Abstract)

Green J.M., Barratt M.J., Kinch M., and Gordon J.I. (2017) “Food and microbiota in the FDA regulatory framework.” Science. 2017 Jul 7;357(6346):39-40. doi: 10.1126/science.aan0836. (Abstract)

Kinch M.S. and Woodard P.K. (2017) “Analysis of FDA-approved imaging agents.” Drug Discov Today. 2017 Jul;22(7):1077-1083. doi: 10.1016/j.drudis.2017.03.006. Epub 2017 Mar 21. (Abstract)

Michael Kinch (2016) “A Prescription for Change: The Looming Crisis in Drug Development” (ISBN-13: 978-1469630625, ISBN-10: 1469630621)

Kinch M.S. and Moore R. (2016) “Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry.” Cell Chem Biol. 2016 Jun 23;23(6):644-53. doi: 10.1016/j.chembiol.2016.05.013. (Abstract)

Books

Prescription for ChangeA Prescription for Change, available from Amazon, Barnes & Noble, and other bookstores.

 

Between Hope and Fear, available from Amazon, Barnes & Noble, and other bookstores.

 

The End of the Beginning: Cancer, Immunity, and the Future of a Cure, available from Amazon, Barnes & Noble, and other bookstores.